JGC
PACB icon

J. Goldman & Co’s Pacific Biosciences PACB Stock Holding History

J. Goldman & Co’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-97,600
Closed -$687K – 374
2016
Q2 		$687K Sell
97,600
-200,231
-67% -$1.83M 0.04% 274
2016
Q1 		$2.53M Buy
297,831
+247,831
+496% +$2.44M 0.16% 158
2015
Q4 		$657K Buy
+50,000
New +$449K 0.07% 197

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

J. Goldman & Co's PACB Position: Q3 2016 in Review

J. Goldman & Co sold out of Pacific Biosciences (PACB) in Q3 2016, closing a stake of 97,600 shares — an estimated $687K sold.

J. Goldman & Co first reported a position in PACB in Q4 2015 and held it in 3 quarters. The position peaked at $2.53M in Q1 2016. 128 funds tracked by Wall St. Rank hold PACB as of Q3 2016.

  • J. Goldman & Co reported no remaining Pacific Biosciences position as of Q3 2016 after selling out during the quarter.
  • J. Goldman & Co sold 97,600 Pacific Biosciences shares in Q3 2016, an estimated $687K.
  • J. Goldman & Co first reported a position in Pacific Biosciences in Q4 2015 and held it in 3 quarters.
  • J. Goldman & Co's Pacific Biosciences position peaked at $2.53M in Q1 2016.
  • 128 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2016.

Based on J. Goldman & Co's 13F filing for Q3 2016, filed 14 Nov 2016.